Loading...
•
Sep 30, 2023
Personalis Q3 2023 Earnings Report
Personalis' Q3 2023 revenue increased by 23% year-over-year, driven by growth in pharma tests, enterprise sales, and population sequencing.
Key Takeaways
Personalis, Inc. reported a 23% increase in third quarter revenue to $18.2 million compared to the same period last year. The company presented data supporting Next Personal’s market leading sensitivity for cancer recurrence detection and increased full year guidance.
Achieved third quarter revenue of $18.2 million, representing a 23% increase over the same period of the prior year
Presented compelling clinical data from the collaboration with the TRACERx consortium for lung cancer, showing higher sensitivity and earlier identification of lung cancer.
Launched NeXT Personal to robust demand as a clinical laboratory-developed test (LDT) for use by oncologists
Company is focusing on driving towards Medicare coverage for NeXT Personal.
Revenue by Segment
Forward Guidance
Personalis expects total company revenue between $19 to $20 million and revenue from pharma tests, enterprise sales, and other customers between $18.5 to $19.5 million, and revenue from population sequencing of approximately $0.5 million for the fourth quarter of 2023.
Positive Outlook
- Total company revenue between $19 to $20 million
- Revenue from pharma tests, enterprise sales, and other customers between $18.5 to $19.5 million
- Revenue from population sequencing of approximately $0.5 million
- Total company revenue between $73 to $74 million for full year 2023
- Revenue from pharma tests, enterprise sales, and all other customers between $64 to $65 million, and revenue from population sequencing of approximately $9 million for full year 2023
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...